Genome-wide view of cell fate specification: *ladybird* acts at multiple levels during diversification of muscle and heart precursors

Guillaume Junion,¹ Laetitia Bataillé, Teresa Jagla, Jean Philippe Da Ponte, Romain Tapin, and Krzysztof Jagla²

Institut National de la Santé et de la Recherche Médicale (INSERM) U384, 63000 Clermont-Ferrand, France

Correct diversification of cell types during development ensures the formation of functional organs. The evolutionarily conserved homeobox genes from *ladybird/Lbx* family were found to act as cell identity genes in a number of embryonic tissues. A prior genetic analysis showed that during *Drosophila* muscle and heart development *ladybird* is required for the specification of a subset of muscular and cardiac precursors. To learn how *ladybird* genes exert their cell identity functions we performed muscle and heart-targeted genome-wide transcriptional profiling and a chromatin immunoprecipitation (ChIP)-on-chip search for direct *Ladybird* targets. Our data reveal that *ladybird* not only contributes to the combinatorial code of transcription factors specifying the identity of muscle and cardiac precursors, but also regulates a large number of genes involved in setting cell shape, adhesion, and motility. Among direct *ladybird* targets, we identified *bric-a-brac 2* gene as a new component of identity code and *inflated* encoding α PS2-integrin playing a pivotal role in cell-cell interactions. Unexpectedly, *ladybird* also contributes to the regulation of terminal differentiation genes encoding structural muscle proteins or contributing to muscle contractility. Thus, the identity gene-governed diversification of cell types is a multistep process involving the transcriptional control of genes determining both morphological and functional properties of cells.

[Keywords: Cell fate; microarray; ChEST; *Drosophila*; *ladybird*; muscle; heart]

Supplemental material is available at <http://www.genesdev.org>.

Received April 17, 2007; revised version accepted October 4, 2007.

Diversification of cell types is crucial for correct progression through development. Genetic studies highlight the essential role of the regulatory inputs, which set up the cell fate-specifying combinatorial code of transcription factor activities, the identity gene code (Carmena et al. 1998; Halfon et al. 2000; Jagla et al. 2002; Zaffran and Frasch 2002; Liu et al. 2006; Estrada et al. 2006). The identity gene code is commonly used to ensure diversification of cells in a broad range of developing tissues and metazoan organisms (Briscoe et al. 2000; Jagla et al. 2002; Buckingham 2003; De Graeve et al. 2004; Certel and Thor 2004). However, our understanding of the global gene expression program that operates downstream from the identity gene code and leads to the acquisition of a given cell fate remains very limited. A large number of key transcriptional regulators acting as cell fate-specify-

ing genes have been identified in *Drosophila* (for review, see Skeath 1999; Baylies and Michelson 2001; Riechmann and Ephrussi 2001; Fichelson et al. 2005; Olson 2006). Particularly well suited to studying cell fate acquisition are *Drosophila* somatic muscles and cardiac cells for which the majority of cell types can be identified by specific molecular markers. Prior studies (Xu et al. 1998; Halfon et al. 2000; Lee and Frasch 2000) revealed that an interplay of Wg, Dpp, and RTK signals was required to switch on expression of the selector genes *twist* (*twi*) and *tinman* (*tin*), whose activity is essential for the initiation of somatic muscle and cardiac development programs. It has also been demonstrated that the same extrinsic regulatory inputs supplemented by the intrinsic *Twi* and *Tin* action activate the cell fate-specifying factors within the cardiac and somatic mesoderm (for review, see Frasch 1999a,b). For example, the regulatory requirements for the specification of a dorsally located DA1 muscle founder and a pericardial cell founder expressing *even-skipped* (*eve*) have been described in detail (Halfon et al. 2000). This led to the identification of *eve* enhancer carrying binding sites for the

¹Present address: European Molecular Biology Laboratory (EMBL) Meyerhofstrasse 1, D-69117 Heidelberg, Germany.

²Corresponding author.

E-MAIL christophe.jagla@u-clermont1.fr; FAX 33-4-73276132.

Article is online at <http://www.genesdev.org/cgi/doi/10.1101/gad.437307>.

effectors of Wg, Dpp, and RTK signaling pathways and for tissue-specific factors Twi and Tin. All these factors are required for the initiation of *eve* expression in dorsal mesodermal cells, whereas repression by identity genes *ladybird* (*lb*) and *msh* ensures restriction of *eve* expression to the DA1 muscle founder and two pericardial cells (Jagla et al. 2002). The finding that a tissue domain is determined by the coordinated action of exogenous signaling cues and endogenous tissue-specific selector genes inspired a CodeFinder approach (Philippakis et al. 2006). This approach was recently used to uncover a large number of regulatory modules regulated by the interplay of the signals mentioned above and muscle- or heart-specific factors. The CodeFinder and a few other approaches (Rebeiz et al. 2002; Zhou and Wong 2004) provided the first genome-wide data sets describing the activity of genes during the determination of muscular and cardiac tissue progenitors. Likewise, transcriptional profiling and chromatin immunoprecipitation (ChIP)-on-chip assays have identified a broad set of genes and their regulatory motifs regulated by the key muscle and heart differentiation factor Mef2 (Junion et al. 2005; Sandmann et al. 2006).

Altogether, the recently reported global approaches dedicated to the muscle developmental program have identified clusters of genes expressed specifically in founder cells, fusion-competent myoblasts, and in differentiating muscle fibers. However, no systematic genome-wide analysis has been performed to identify downstream targets of identity genes required for the diversification of muscle and heart cells. To address this issue, we set out to identify genes whose expression was regulated by Lb homeodomain factors known to be required for the specification of segmental border muscle and a small subset of cardiac precursors (Jagla et al. 1997, 1998).

It had been shown previously that *ladybird early* (*lbe*) and *ladybird late* (*lbl*) genes acted as repressors contributing to the cell identity code during *Drosophila* founder cell diversification (Jagla et al. 1999, 2002). Importantly, previous genetic analyses revealed that muscle founder cells carry all the information required for correct shape, innervation, and attachment of different muscle fibers strongly suggesting an instructive role of identity genes in these processes. The phenotypes observed in *lb* mutant embryos (Jagla et al. 1998) suggested a role of *lb* genes in axial positioning of muscle precursors and in the acquisition of fiber-specific shape and attachment to tendon cells. Interestingly, the vertebrate *lb* orthologs *Lbx1* genes play similar roles during the specification of neural fates (Cheng et al. 2005) and during the setting of properties in mouse, chick, and zebrafish appendicular muscle precursors (Brohmann et al. 2000; Gross et al. 2000; Neyt et al. 2000; Mootoosamy and Dietrich 2002).

Thus, *lb/Lbx1* genes emerge as evolutionarily conserved cell identity factors whose ability to specify cell fates is employed in different tissue contexts and in a broad range of animal species. Hence, the unveiling of the global gene expression program operating downstream from *lb* should provide a general view of how the

acquisition of cell identity is executed at the genome level. To approach this issue we designed a targeted transcriptional profiling strategy and used it in combination with the recently described (Junion et al. 2005) ChIP-enriched in silico target (ChEST) technique. Our data show that *lb* acts at multiple levels and over a long time period. During myogenic determination steps it represses a subset of identity genes and contributes to the cell fate-specifying code of transcription factors. Later, it contributes to the acquisition of individual properties of muscle and cardiac cells by acting as a regulator of genes involved in setting cell shape, cell motility, and function.

Results

Uncovering transcriptional Lb targets using targeted expression profiling

The gene *lb*, like many other cell identity genes, is expressed in a very restricted population of embryonic cells, making the identification of its transcriptional targets in the whole embryo particularly challenging. In each hemisegment within the somatic and cardiac mesoderm, *lb* is expressed in one out of 30 precursors of somatic muscles and in four out of 16 cardiac precursors (see Fig. 1A; Jagla et al. 1997, 1998). Unlike highly restricted spatial expression, timely, *lb* is expressed during a large time window (see Fig. 1A). Its expression is initiated at 5 h AEL (after egg laying) when the diversification of mesodermal cell types starts, and is maintained until the late steps of muscle and heart morphogenesis indicating potential role of *lb* in progressive acquisition of specific muscle and cardiac cell properties. To optimize the identification of mesodermal *lb* targets we opted to use muscle and heart-targeted overexpression or RNA interference (RNAi)-based attenuation of *lb*. Thus, to design a targeted expression profiling adapted to muscular and cardiac tissues and to the timing of *lb* activity we opted for two different mesodermal drivers: (1) the pan-mesodermal *24B-GAL4* driver (H + M-targeting) and the heart-specific *tin-GAL4* driver (H-targeting) (see Fig. 1A). The *24B-GAL4* driver's activity overlaps with all the steps of heart- and muscle-specific *lb* expression, whereas the cardiac *tin-GAL4* driver is expressed from 9 h AEL onward and targets the later aspects of cardiogenic *lb* functions. Within the targeted tissues, and especially in the heart, the proportion of *lb*-positive cells is relatively high (~18% in the cardiac mesoderm), thus increasing the probability of targets identification.

To reduce the number of false positives, we performed three independent RNA isolations from staged [5- to 16-h-AEL) wild-type (*white*¹¹¹⁸) embryos or staged embryos collected from crosses of *UAS-lb* or *UAS-lbRNAi* (Maqbool et al. 2006) flies with one of the targeting drivers (Supplementary Fig. S1A). Thus, for each experimental condition three independent cDNA probes were used and three global GeneChip data sets were generated (Supplementary Fig. S1A). The data sets (ArrayExpress

Figure 1. Identification of Lb target genes by expression profiling and ChEST strategies. (A) Muscle- and heart-specific expression of *lb* and the two drivers (*24B > GFP* and *tin > GFP*) used for targeted transcriptional profiling. Three different embryonic stages are presented to illustrate Lb and *24B-GAL4* expressions in biological samples used for microarray experiments. In the first column (5–9 h AEL) are shown embryos at stage 11 or early stage 12 (lateral views). In the *middle* column (9–12 h AEL) are embryos at stage 13, and in the third column (12–16 h AEL) are shown embryos at stage 15–16. In the *middle* and *right* column, muscle (M) expression is illustrated by lateral views and heart (H) expression by dorsal views of embryos. Note that *tin-GAL4* driver expression starts later, from stage 13, and persists until the late embryogenesis. To obtain wild-type biological samples for microarray and ChEST experiments, three collections of embryos aged from 5 to 16 h AEL have been used. In a similar manner, F1 embryos from the cross of *24B-GAL4* with *UAS-lbe* and with *UAS-lbRNAi* lines were collected and used as H + M GOF and H + M LOF samples, respectively. Embryos from the cross of *tin-GAL4* with *UAS-lbe* or *UAS-lbRNAi* lines were aged according to *tin-GAL4* expression and later labeled H GOF and H LOF, respectively. (B) Venn diagrams showing populations of candidate genes identified by comparison of GOF versus wild-type, LOF versus wild-type, and GOF versus LOF context. Note that in H conditions more candidate genes are common for these three candidate gene populations than in H + M context. (C) Main categories of Lb targets identified by

targeted expression profiling. GO-based statistical distribution of genes identified in H + M targeting conditions and H targeting conditions. In both contexts we find an important enrichment for ECM and cytoskeleton components, signaling molecules, proteins involved in proteolysis, ATP binding, and factors carrying a DNA- or RNA-binding domain. Note that >50% of identified genes have no GO annotations and ~17% have a GO, which does not fit into any of the five main categories. (D) Genome scanning strategy for Lb-binding CRMs. Different heart (H) targeting and muscle (M) targeting genome scanning conditions were used (asterisk; see Supplemental Material). A pool of predicted cardiac and muscular Lb-dependent CRMs was filtered with respect of distance to adjacent genes and their annotations (asterisk; see Supplemental Material). Selected CRMs were spotted to produce a computed Lb-CRM array. In parallel, a pool of DNA fragments bound in vivo by Lb was isolated by ChIP and used to probe the computed array. Among 74 CRMs spotted, 16 were found enriched in ChIP material. (E) Identification of the in vitro consensus binding site for Ladybird. Random 10-nt-long oligos flanked on 5' and 3' by 20-nt primer-compatible sequences were radiolabeled and used for the SELEX approach. Four cycles of incubation with 6xHis-Lb homeodomain fusion protein followed by the amplification of a selected subset of sequences were applied to select motifs bound preferentially by Lb. As shown by shift assays, Lb homeodomain (top panels) and both Lbe and Lbl proteins (bottom panel) recognize sequences containing TAAT and TAAC core motifs, and the deduced consensus sequence is RYVTAAYHAG.

accession no. E-TABM-297) were normalized, and classified using SAM analysis (Supplementary Tables S1–S4; see Materials and Methods for details). Based on this selection, we found 2663 genes with significantly altered transcription levels in H-targeting conditions and 1931 in an H + M-targeting context. Comparison of H and H + M targets revealed that 1118 genes were identified in both targeting contexts (Supplementary Table S5). Within the groups, the candidate genes could be subdivided into those regulated positively and those whose

expression was down-regulated by *lb*. Comparison of candidate genes identified in *lb* gain-of-function (GOF) conditions with those from the *lb* RNAi conditions revealed that several genes display opposite changes in their transcription levels (see Supplementary Table S6). Moreover, as shown by Venn diagrams (Fig. 1B), an important number of candidate genes appear common when comparing pool of GOF versus wild-type candidates with LOF versus wild-type and with GOF versus LOF candidates. Overlapping populations of candidate

Junion et al.

Table 1. Selected GO-enriched microarray candidate genes and the ChEST-identified direct *Lb* targets

(A) Microarray candidate genes from H + M targeting conditions

Affy id	Gene name	Function	Expression	Fold change	<i>q</i> value (%)	Validation
ECM and cytoskeleton						
Cell adhesion and cell motility						
1632744_a_at	<i>if</i>	Integrin receptor, muscle attachment	SM	+1.54	5.72	RT/QRT/Ab
1633428_at	<i>prc</i>	ECM component, cell migration	DV	+2.04	2.2	Ab (n.s.)
1639229_at	<i>vkg</i>	ECM component	DV Hem	+2.12	2.61	QRT
1633286_at	<i>CG32372</i>	Cell adhesion	meso	+2.04	3.85	ND
1635370_at	<i>Tsp42E1</i>	Integral to membrane	DV	+2.32	1.82	ND
1632968_at	<i>CG6053</i>	Microtubule-based movement	ND	+8.35	3.71	ND
1637232_at	<i>CG17150</i>	Microtubule-based movement	ND	+6.5	3.71	ND
1627859_at	<i>CG31646</i>	Cell-cell adhesion signal transduction	ND	+4.17	2.61	ND
1633167_s_at	<i>CG6788</i>	Cell adhesion molecule	ND	+1.98	5.72	ND
Muscle structure and function						
1628671_a_at	<i>sls</i>	Myosin light chain kinase activity, muscle contraction	SM	+2.17	4.52	Ab
1632945_at	<i>Msp-300</i>	Actin binding, dsRNA binding	DV and SM	+1.93	2.18	RT/Ab
1630261_a_at	<i>up</i>	Troponin binding, troponin complex	SM	+1.72	5.72	RT
1630509_at	<i>Mp20</i>	Actin binding, muscle contraction	SM	+1.78	2.93	QRT
1624746_at	<i>βTub85D</i>	Microtubule intracellular transport	SM	+4.76	1.4	ND
1626397_at	<i>bt</i>	Muscle contraction kinase activity, constituent of cytoskeleton	SM	+2.32	2.11	ND
1625825_at	<i>SPARC</i>	Calcium ion binding, structural molecule activity	Meso	+1.96	1.4	ND
1629235_s_at	<i>wupA</i>	Actin binding, troponin complex	SM	+1.88	2.47	ND
Cell signaling						
Cell communication						
1629164_at	<i>CG9825</i>	High-affinity inorganic phosphate:sodium symporter activity	ND	+2.44	1.42	ND
1627067_at	<i>CanB2</i>	Calcium-binding neurotransmitter	SM	+2	1.18	ND
1630778_at	<i>CG10116</i>	Lipoprotein lipase	ND	+1.88	2.61	ND
1636378_a_at	<i>Syn</i>	Neurotransmitter secretion	ND	+6.67	2.5	ND
1637674_at	<i>Ace</i>	Neuromuscular synaptic transmission	ND	+5.14	2.23	ND
1625065_s_at	<i>SK</i>	Small conductance calcium-activated potassium channel	ND	+3.22	2.11	ND
Signaling pathways						
1627882_at	<i>dlg1</i>	Plasma membrane, cell cortex EGFR binding	ND	+2.5	1.82	RT
1634580_at	<i>bsk</i>	MAPK dorsal closure, frizzled, and Jun pathway	ND	+1.92	5.72	RT
1630560_s_at	<i>Gyc 76C</i>	Intracellular signaling cascade	SM	+2.42	7.19	ND
1624389_at	<i>CG7526</i>	Cell communication transmembrane receptor protein tyrosine kinase activity	SM	+2.5	1.82	ND
1622957_s_at	<i>Rep3</i>	Apoptosis	ND	+16.67	5.09	ND
1640325_at	<i>CG8641</i>	RAS small monomeric GTPase	ND	+14.28	1.42	ND
1624636_at	<i>CG5712</i>	Adenylate cyclase	ND	+10	1.18	ND
1634436_at	<i>Ast-C</i>	Regulation of heart	ND	+3.7	1.06	ND

continued on next page

Multistep acquisition of cell identity

Table 1. (continued)

Affy id	Gene name	Function	Expression	Fold change	q value (%)	Validation
1630285_at	<i>RhoGAP100F</i>	GTPase activator intracellular signaling	ND	+2.27	3.85	ND
1635009_at	<i>CG8500</i>	RAS small monomeric GTPase	ND	+2.27	3.22	ND
1639502_at	<i>CG8942</i>	Wnt receptor signaling pathway	ND	+2.17	1.82	ND
1625478_at	<i>Mnn1</i>	JNK cascade MAPKKK cascade	ND	+1.54	2.5	ND
1637438_at	<i>Wnt2</i>	frizzled2 signaling	ND	-1.6	5.72	RT
1629844_s_at	<i>rap</i>	Cyclin catabolism	CB PC	-1.55	3.22	ND
1634994_a_at	<i>RacGAP84C</i>	RAS GTPase activator	ND	-2.94	3.49	ND
DNA and RNA binding						
1637943_at	<i>how</i>	mRNA binding, mesoderm dev	SM DV	+1.81	2.47	ND
1627436_s_at	<i>pdp1</i>	Par-domain protein leucine zipper factor mesoderm dev	SM	+1.69	3.71	QRT
1633789_at	<i>Hand</i>	Regulation of transcription	meso DV Hem	+1.54	3.71	ND
1624520_a_at	<i>ftz-f1</i>	Regulation of transcription from RNA polymerase II promoter	CB	+1.67	3.22	ND
1633351_at	<i>CG10384</i>	Apoptosis/cell proliferation	ND	+5.88	2.23	ND
1623880_at	<i>CG7274</i>	Cell cycle	ND	+3.33	2.61	ND
1636710_at	<i>Neu2</i>	Transcription regulator activity cell proliferation	ND	+2.56	2.61	ND
1627734_at	<i>nau</i>	bHLH factor	SM	-2.67	2.61	Ab
1629368_at	<i>slou</i>	Homeobox gene cell fate specification	SM	-1.62	1.82	Ab
1626834_at	<i>CG8277</i>	Translation initiation factor	ND	-5.23	3.49	ND
1638749_at	<i>CG32611</i>	Nucleic acid binding	ND	-3.97	3.49	ND
Proteolysis						
1635183_at	<i>Spn43Ab</i>	Serine protease inhibitor	ND	+1.72	2.47	RT
1626394_at	<i>Jon99Fi</i>	Chymotrypsin	ND	+21.48	10.01	ND
1630547_at	<i>CG4723</i>	Endothelin-converting enzyme	ND	+10	2.23	ND
1629618_at	<i>CG12256</i>	Serine-type endopeptidase	ND	+6.26	1.32	ND
1638196_at	<i>αTry</i>	Proteolysis and peptidolysis	ND	+2.94	1.62	ND
1637986_at	<i>CG15253</i>	Metalloendopeptidase activity	ND	+2.78	3.85	ND
1629858_at	<i>CG2528</i>	Prolyl aminopeptidase	ND	-3.36	5.72	ND
ATP binding/mitochondria						
1623770_at	<i>CG1673</i>	Transaminase activity	ND	+1.59	2.47	RT
1639825_at	<i>comt</i>	Golgi organization and biogenesis	SM DV	+1.56	4.52	ND
1635632_at	<i>CG18363</i>	Mitochondrial membrane	ND	+8.17	8.34	ND
1629643_at	<i>CG32186</i>	ATP-binding cassette (ABC) transporter	ND	+6.69	4.33	ND
1640231_a_at	<i>CG8908</i>	ATP-binding cassette (ABC) transporter	ND	+2.53	2.5	ND
1631731_at	<i>CG1494</i>	ATP-binding cassette (ABC) transporter	ND	-4.82	1.36	ND

(B) Microarray candidate genes from M targeting conditions

ECM and cytoskeleton**ECM and cell motility**

1631756_at	<i>CG10859</i>	Microtubule-based movement	ND	+6.25	2.37	ND
1623412_a_at	<i>CG17150</i>	Dynein ATPase	ND	+4.77	7.48	ND
1637488_at	<i>Cad88C</i>	Calcium-dependent cell adhesion	ND	+2.37	0	ND
1629012_at	<i>capt</i>	Actin polymerization and/or depolymerization	ND	+1.69	5.46	ND
1630304_at	<i>Dhc93AB</i>	Dynein complex motor activity	ND	-3.33	6.29	RT
1631881_a_at	<i>sli</i>	ECM component, receptor binding	DV and SM	-3.27	5.46	QRT
1641442_a_at	<i>trol</i>	ECM cell-cell adhesion	DV	-2.38	3.93	RT
1633428_at	<i>prc</i>	ECM component, cell migration	DV	-2.44	0	Ab (n.s.)

continued on next page

Junion et al.

Table 1. (continued)

Affy id	Gene name	Function	Expression	Fold change	q value (%)	Validation
1639613_at	<i>shg</i>	Calcium-dependent cell adhesion, adherens junction	DV	-1.86	3.75	RT
1634290_a_at	<i>mew</i>	Integrin complex receptor activity	SM CB	-1.53	5.46	ND
1639229_at	<i>vkg</i>	ECM component	DV Hem	-2.13	3.93	ND
1637137_a_at	<i>Dhc64C</i>	Microtubule-based motility	ND	-5.33	3.82	ND
1637848_at	<i>CG6873</i>	Actin binding	ND	-4.38	6.35	ND
1632164_at	<i>scrib</i>	Establishment and/or maintenance of epithelial cell polarity	ND	-2.17	7.48	ND
Muscle structure and function						
1626452_at	<i>CG8698</i>	Muscle contraction	SM	-1.8	4.6	RT
1628671_a_at	<i>sls</i>	Myosin light-chain kinase activity, muscle contraction	SM	-1.88	3.93	Ab
1632945_at	<i>Msp300</i>	Actin binding, dsRNA binding	DV and SM	-2.28	4.07	Ab
1630261_a_at	<i>up</i>	Troponin binding, troponin complex	SM	-1.88	0	RT
1638818_at	<i>Mlp60A</i>	Lim muscle protein, protein binding	SM	-2.08	0	RT
1631217_a_at	<i>TpnC73F</i>	Calmodulin-binding muscle contraction	SM	-3.45	3.93	ND
1634436_at	<i>Ast2</i>	Regulation of heart contraction rate	ND	-3.12	3.61	ND
1630509_at	<i>Mp20</i>	Actin binding, muscle contraction	SM	-2.38	6.54	ND
DNA and RNA binding						
Cell fate specification						
1637278_at	<i>tin</i>	Homeodomain transcription factor	DV and SM	+1.74	3.7	Ab (n.s.)
1630010_a_at	<i>pnt</i>	ETS domain transcription factor	DV	+2.22	6.98	RT
1629459_at	<i>Doc3</i>	Transcription factor	CB	+1.63	7.48	ND
1624060_at	<i>bab2</i>	BTB POZ factor	DV and SM	-1.92	3.75	QRT/Ab
1636558_a_at	<i>Abd-A</i>	Heart proper cell fate commitment	CB	-1.98	4.6	ND
Others						
1636780_at	<i>meso18E</i>	Mesoderm development	SM	-2.35	4.92	RT
1632237_at	<i>Rx</i>	Paired-like homeobox	DV	-7.14	3.93	ND
1636679_at	<i>Mrtf</i>	Mesodermal cell migration, GO:0030036 actin cytoskeleton organization, and biogenesis	DV and SM	-2.02	5.46	ND
1631948_s_at	<i>Clk</i>	bHLH factor	ND	-9.46	2.49	ND
Cell signaling						
Cell communication						
1641460_at	<i>CanB</i>	Calcium-binding neurotransmitter	ND	+2.04	5.75	QRT
1634498_at	<i>CG17152</i>	Glutamate-gated ion channel	ND	+4.65	4.65	ND
1631846_at	<i>CG14857</i>	Organic cation porter	ND	-8.01	2.18	ND
1641495_at	<i>pHCL-A</i>	Glycine-gated chloride channel complex	ND	-6.52	4.38	ND
Rho/PI3K/CDK						
1635592_at	<i>vav</i>	Rho protein signal transduction, regulation of cell shape	ND	+2.08	2.89	RT
1641006_s_at	<i>PI3K68D</i>	Intracellular signaling	ND	+2.04	3.82	ND
1635062_at	<i>Smg1</i>	Phosphatidylinositol 3-kinase	ND	+1.53	3.7	ND
1625199_s_at	<i>dap</i>	Cyclin-dependent protein kinase inhibitor	meso	-2.05	4.6	RT

continued on next page

Multistep acquisition of cell identity

Table 1. (continued)

Affy id	Gene name	Function	Expression	Fold change	q value (%)	Validation
1641322_at	<i>Pde9</i>	cGMP-specific phosphodiesterase	ND	-5.66	4.09	ND
1636914_at	<i>Cdk5α</i>	Cyclin-dependent protein kinase	ND	-1.67	3.93	ND
1640657_at	<i>RhoGAP102A</i>	Rho GTPase activator	ND	-1.56	7.48	ND
MAPK signaling						
1640325_at	<i>CG8641</i>	RAS small monomeric GTPase	ND	+12.5	4.09	ND
1629678_a_at	<i>Aplip1</i>	Regulation of JNK cascade	ND	+1.58	4.86	ND
1641253_at	<i>Src64B</i>	Tyrosine kinase Jun pathway	SM	-1.64	3.48	ND
Other signalings						
1623324_at	<i>lin</i>	Torso signaling pathway	meso	+1.89	2.37	ND
1627328_at	<i>scw</i>	BMP receptor signaling pathway	ND	+11.11	4.92	ND
1626723_at	<i>Takr86C</i>	G-protein-coupled receptor protein signaling pathway	ND	+10	2.37	ND
1637339_at	<i>Ccap</i>	Positive regulation of heart contraction	ND	+2.43	6.29	ND
1625636_s_at	<i>pan</i>	Wnt receptor signaling pathway	DV and SM	-1.58	0	ND
1632457_s_at	<i>mam</i>	Mesoderm cell fate determination Notch signaling pathway	meso	-1.82	4.86	ND
1628166_a_at	<i>DmsR-2</i>	G-protein-coupled receptor protein signaling pathway	ND	-5.82	3.39	ND
1633461_at	<i>slik</i>	Receptor signaling protein serine-threonine kinase	ND	-5.55	5.46	ND
Apoptosis						
1633498_at	<i>CG7188</i>	Apoptosis inhibitor	ND	+2.08	4.07	ND
1639071_a_at	<i>Dredd</i>	Apoptosis caspase	ND	-1.63	5.75	RT
1624441_at	<i>CG18389</i>	Induction of apoptosis by hormones	ND	-9.1	6.29	
Proteolysis						
1632355_at	<i>lack</i>	TGFβ pathway ubiquitin ligase	ND	+1.85	3.75	RT
1632993_at	<i>CG6372</i>	Leucyl aminopeptidase	ND	+33.3	3.39	ND
1631986_at	<i>CG16998</i>	Serine-type endopeptidase	ND	+4.35	4.38	ND
1624240_at	<i>Uch</i>	Ubiquitin C-terminal hydrolase	ND	+3.7	5.46	ND
1628288_s_at	<i>Nep4</i>	Metalloendopeptidase	DV	-2.78	6.54	ND
1626394_at	<i>Jon99Fi</i>	Chymotrypsin	ND	-10.84	5.75	ND
ATP binding/mitochondria						
1628659_at	<i>Mdr49</i>	ATPase activity, coupled to transmembrane movement of substances	meso	+3.12	6.98	ND
1629643_at	<i>CG32186</i>	ATPase activity, coupled to transmembrane movement of substances	ND	+5.21	4.09	ND
1634045_at	<i>CG10748</i>	Tricarboxylic acid cycle, mitochondrial matrix	ND	-4.54	4.38	ND

(C) Candidate genes and CRMs identified by ChEST with H-targeting conditions

Gene	CRM position	Biological function
<i>sli</i>	D: 11384323-11384549	Receptor binding/mesoderm migration
<i>bab2</i>	I: 1146918-1147918	Regulation of transcription
<i>Dhc93AB</i>	I: 16851421-16852003	Cell motility/microtubule-based movement
<i>Dab</i>	D: 16689242-16689667	Receptor binding/sevenless signaling
<i>lbe</i>	D: 17266296-17266690	Transcription factor/cell fate specification
<i>knrl</i>	Up: 20561047-20561799	Transcription factor
<i>NetA</i>	Up: 14488661-14489438	Cell adhesion/synaptic target attraction
<i>if</i>	I: 16607638-16607929	Muscle attachment/myofibril assembly

continued on next page

Table 1. (continued)

Candidate genes and CRMs identified by ChEST with M-targeting conditions

Gene	CRM position	Biological function
<i>shg</i>	I: 16562257–16562649	Cell adhesion/heart development
<i>CG8698</i>	I: 3918084–3918730	Muscle contraction
<i>how</i>	Up: 17867107–17867556	RNA binding/mesoderm development
<i>CG10116</i>	Up: 13431899–13432764	Phospholipid metabolism
<i>Kr</i>	D: 20746567–20747039	Transcription factor/muscle development
<i>CG5440</i>	D: 1339379–1339655	Ubiquitin-conjugating enzyme
<i>CG8743</i>	I: 19682669–19683045	Lipid metabolism/calcium ion transport
<i>pain</i>	D: 20427913–20428423	Calcium channel activity

The expression profiling candidates from H + M (A) and from H-targeting conditions (B). The candidates are classified on six groups according to GO annotations and listed within the groups in the following order: (1) candidates validated either by RT–PCR (RT), real-time RT–PCR (QRT) or by antibody staining (Ab); (2) candidates with mesodermal expression or function; (3) candidates ranked by the fold change in expression. In bold are validated microarray candidate genes. (SM) Somatic mesoderm; (DV) dorsal vessel; (CB) cardioblasts; (PC) pericardiac cells; (Hem) hemocytes; (Meso) mesoderm, (ND) not determined, [Ab (n.s.)] antibody validation performed but not shown. (C) A list of ChEST-identified CRMs and adjacent target genes. Genes in bold represent the common microarray and ChEST targets.

genes are comparatively smaller in H + M targeting context than in H targeting conditions, mainly due to the relatively restricted number of candidate genes whose expression was significantly altered in *24B > RNAi*lb embryos (LOF vs. wild-type pool).

Main categories of Lb targets identified by expression profiling

We used gene ontology (GO) annotations to classify identified targets and an GO-based analysis (GObat) to identify the significantly enriched GO annotations. In both H + M and H-targeting conditions about one-half of the candidate genes were found to be GO-annotated. This enabled us to subdivide the candidates into six main categories (Fig. 1C) and to identify the overrepresented GO annotations in the gene list (Table 1A,B; Supplementary Fig. S2). The GO-annotated candidate genes with a mesodermal function or mesodermal expression pattern and with a high fold expression change value are listed in Table 1A,B (for the entire list of GO-annotated candidates see Supplementary Tables S1–S3). As expected, we identified a group of already known muscle and heart identity genes (e.g., *nau*, *slou*, *tin*, *Doc3*) as well as potential new components of the cell identity code (e.g., *bab2*, *Pdp1*, *CG32611*). We observed that Lb regulates the transcription of this category of genes either positively or negatively. The Lb-regulated genes identified by expression profiling also code for the extracellular matrix (ECM)/cell adhesion components (e.g., *shg*, *if*, *vkg*, *tril*, *prc*, *slf*) and for proteins involved in the remodeling of actin filaments and in cell motility (e.g., *Dhc93AB*, *Mp20*, *Msp300*, *Pax*, *Vin*). A subset of candidate genes encoding cytoskeletal components is repressed by *lb* in the H context and positively regulated in H + M conditions (Table 1A,B; Supplementary Table S3). To this category belong constituents of the sarcomeric cytoskeleton (e.g., *up*, *Mlp60A*, *Prm*, *sls*) suggesting that their activity contributes to specific properties of *lb*-express-

ing muscles. A large number of GO-enriched identified targets fit into Wnt (e.g., *Wnt2*, *pan*, *Cby*), Rho/Rac (e.g., *RhoGAP100F*, *vav*), and RTK (e.g., *Jon99Fi*, *CG15253*) signaling pathways or are encoding proteins involved in energetic metabolism (e.g., *comt*, *CG32186*) and in protein degradation (e.g., *Spn43Ab*, *gol*).

Interestingly, a similar GO-based distribution of Lb targets was found in H and in H + M targeting conditions (Fig. 1C), indicating that the acquisition of heart and muscle cell identities involves the same categories of genes.

Direct Lb targets revealed by ChEST

To identify Lb-dependent *cis*-regulatory modules (CRMs) and genes directly regulated by Lb in muscle and heart cells we used a ChIP-enriched in silico target approach (ChEST) (Fig. 1D; Supplementary Fig. S1B; Junion et al. 2005). The ChEST assay is based on a combination of computational prediction of TF-binding regulatory modules with ChIP and enabled us to select the CRMs bound in vivo by the factor of interest, *lb* genes code for homeodomain transcription factors thought to bind DNA. However, the DNA sequences to which Lb binds and genes directly regulated by Lb have not yet been described. As the Lb-binding site has not yet been determined we first used the in vitro SELEX approach (Roulet et al. 2002) to identify DNA motifs recognized by Lb protein (Fig. 1E). We found that 6His-LbHomeodomain recombinant protein bound to 10-nucleotide (nt) motifs containing TAAT or TAAC core sequences (Fig. 1E, top panels). These motifs were also specifically recognized by the full-length Lbe and Lbl proteins (Fig. 1E, bottom panel). The alignment of all variants of Lb-bound motifs gave the consensus Lb-binding site RVYTAAYHAG (Fig. 1E), which was used for in silico genome scanning as previously described (Junion et al. 2005). The ChEST strategy adapted for seeking Lb-dependent muscle and heart enhancers (Fig. 1D) consisted of a computer-as-

sisted genome-wide screen for CRMs containing Lb-binding sites clustered with motifs recognized by heart- and muscle-specific factors (see Supplemental Material). The selected CRMs were amplified and spotted to produce a computed Lb-CRM chip. In parallel, a pool of genomic DNA fragments bound by Lb *in vivo* was isolated from whole 5- to 16-h-AEL embryos by ChIP with specific anti-Lb antibody (Fig. 1D). A nonimmune serum was used in a control ChIP assay (see Supplementary Fig. S1B). The ChIP-isolated DNA fragments from three independent experiments were labeled and used as a probe for the Lb-CRM chip to identify ChIP-enriched CRMs. Using heart (H) targeting and muscle (M) targeting conditions (see Materials and Methods) we predicted 336 potential H + M Lb-dependent CRMs, from which after stringent gene annotation-based filtering (see Supplemental Material for details) 74 CRMs were selected and spotted to produce an Lb-CRM array. From this pool, 16 CRMs were found to be significantly enriched after hybridization with the Lb-ChIP probe (Table 1C; Supplementary Table S7). The restricted number of ChEST-revealed Lb targets results most probably from the applied stringent *in silico* filtering procedure and the small proportion of mesodermal cells expressing Lb proteins in ChIP samples. Nevertheless, the ChEST-identified target genes fit into the same categories as the microarray-revealed candidates, thus confirming the global view of Lb transcriptional targets. Importantly, eight out of 16 ChEST-CRMs lie in the vicinity of microarray-identified candidate genes (bold candidates in Table 1C). Among the common ChEST/microarray targets are genes encoding transcription factors (*bab2*), setting cell shape, motility, and adhesion (*slf*, *Dhc93AB*, *shg*, *CG10116*), and also involved in later aspects of muscle differentiation and function (*if*, *how*, *CG8698*).

*l*b regulates expression of microarray and ChEST-identified candidate genes

To validate the microarrays data we tested the expression of candidates from each target's category by RT-PCR, real-time RT-PCR (Fig. 2A,A',B; Supplementary Table S8), or if available, by antibody staining (Fig. 2C–J). In all the cases tested, changes in the expression of candidate genes agreed with microarray data. For example, *shg* expression decreased by about half in heart-specific *l*b-GOF embryos in both microarrays and in RT-PCR (see Table 1B; Fig. 2A; Supplementary Table S8), whereas the level of *slit* transcript (detected by microarrays and by real-time RT-PCR) was consistently higher in the H + M *l*b-LOF context (Table 1A; Supplementary Table S8). The changes in candidate gene expression induced by *l*b LOF or GOF are also seen at protein levels (Fig. 2C–J). We found that the reduced expression of *slouch* (*slou*) and *nautilus* (*nau*) in *l*b H + M GOF embryos detected in microarrays correlated with the loss of muscle-specific Slou and Nau stainings in embryos overexpressing Lbe under the control of a *24B-GAL4* driver (Fig. 2C–F). The capacity of Lb to act as an activator and regulate expression of genes encoding muscle structure com-

ponents is illustrated by accumulation of Sallimus (Sls) and Msp300 proteins in muscles ectopically expressing Lbe (Fig. 2G–J).

To confirm that the ChEST-identified CRMs act as bona fide enhancers *in vivo* we generated transgenic reporter lines carrying Lb-dependent modules close to *bab2* and *if* genes (Fig. 2K,P), which are heart and muscle Lb targets common for ChEST and microarray assays (Table 1C). The role of *l*b in regulation of *bab2* and *if* expression was validated by real-time RT-PCR (Fig. 2A'). In the case of *bab2* CRM (Fig. 2K–O) we found that GFP expression in the transgenic reporter line recapitulated cardiac *bab2* expression starting from stage 13. In microarray experiments (Table 1B) and in real-time RT-PCR validation tests (Fig. 2A'; Supplementary Table S8) *bab2* was found to be negatively regulated by Lb, so we decided to test whether the *bab2* CRM-driven expression of *GFP* (*bab2-GFP*) was influenced by pan-mesodermal overexpression of Lbe. Interestingly, we observe two distinct effects. In embryos at early stage 13, *bab2-GFP* expression was down-regulated in cardiac primordia (Fig. 2M) indicating that at the beginning of cardiogenesis Lb acts as direct repressor of *bab2* excluding its activity from Lb-positive cells. In embryos at stage 14 and older Lb no longer acted as a *bab2* repressor. We observed instead that GFP expression was enhanced in the *l*b GOF context (Fig. 2O) indicating a switch from a repressive to an activating action of Lb. Overall, these data reveal that Lb directly represses *bab2* expression during early steps of cardiac cell fate specification, and later on acts as its activator most probably by interacting with different cofactors.

The ChEST-identified *if* CRM (Fig. 2P–R) also acts as an enhancer *in vivo*. It drives *lacZ* expression in a restricted subset of lateral muscles with the most prominent expression in the Lb-positive SBM (segment border muscle) (Fig. 2Q). To test whether Lb is able to regulate positively *if* via the identified CRM we analyzed *if-lacZ* expression in embryos expressing Lbe ubiquitously in all muscle cells. As shown in Figure 2R, *lacZ* expression is ectopically expanded indicating that Lb is able to act as an *if* activator. *if* codes for α -PS2 integrin and is known to play important roles in muscle attachment and sarcomeric assembly (Bloor and Brown 1998; Brown et al. 2000). In embryos, If accumulates as a heterodimer with β -PS-integrin, Myospheroid (Mys) at extremities of growing myotubes where it is required for interaction with ECM ligands such as Tigrin to facilitate muscle-tendon and muscle-muscle contacts (Brown et al. 2000). It has been proposed that by interactions with the ECM-forming proteins (Collagens, Laminins) outside the cell and with actin-binding proteins such as Talin, Vinculin, and α -actinin within the cell If ensures a link between adhesion and cell shape. Hence, identifying *if* as a direct Lb target provided a strong line of evidence that Lb regulates morphological and dynamic properties of cells and is able to influence late aspects of muscle differentiation. Thus, Lb appears to directly regulate genes whose activity ranges from the cell fate determination to the late aspects of cell-type-specific differentiation.

Figure 2. Validation of selected Lb targets identified by expression profiling and ChEST approaches. (A,B) RT-PCR analyses of transcript levels in wild type and in *lb* GOF or LOF conditions for candidates identified in H targeting (A) and H + M targeting (B) conditions. At least two candidate genes from each of main categories have been analyzed (see also Table 1A,B).

(A') Real-time RT-PCR validation of additional candidates. Relative quantity of gene transcripts in GOF H + M, LOF H + M, or GOF H contexts versus wild type are presented (see Materials and Methods and Supplementary Table S8 for details). Alterations in candidate gene expression observed in RT-PCR and real-time RT-PCR experiments are consistent with expression changes identified by microarrays. Lateral views of stage 14 (C,D,G–J) and stage 13 (E,F) embryos. *lb* is able to repress (C–F) certain target genes and to activate (G–J) others. (C–F) Expression of muscle identity gene *slou* (C) and *nau* (E) are repressed by *lb* in *24B > lbe* embryos (arrows in D,F). (G–J) Expression of Sls, a component of sarcomeric cytoskeleton (G) and a dystrophin related Msp300 (I) are ectopically activated (arrows in H,J) in *lbe* GOF conditions. Arrowheads and arrow indicate increased Sls (H) and Msp300 (J) level in the SBM and the ventral muscles, respectively. *bab2* (K–O) and *if* (P–R) CRMs act as Lb-dependent regulatory regions in vivo. (K,P) A scheme showing the position and organization of Lb-dependent CRMs located within the first *bab2* (K) and *if* (P) intron. Positions of Lb, Tin, Twi, Dmef2, and dTCF-binding sites are indicated. (L) Wild-type expression of *bab2-GFP* line (carrying Lb-dependent CRM) showing that GFP expression is initiated in *lbe* cardiac cells at stage 13. Notice that initially in each hemisegment only one out of two *lbe*-positive cardioblasts express GFP. GFP expression also coincides with endogenous *Bab2* expression. (M) Wild-type *bab2-GFP* expression in stage 14 embryo showing that during later steps of cardiac development the CRM drives expression in an enlarged population of cardiac cells including *lbe*-negative cardioblasts. GFP is coexpressed with endogenous *Bab2*. (N) *bab2-GFP* expression is not seen at stage 13 in embryos overexpressing *lbe* in mesodermal cells, suggesting that during early stages of heart development *lb* is able to repress *bab2*. (O) In stage 14 embryo overexpressing *lbe*, *bab2-GFP* is no longer repressed, indicating that the repressive influence of *lbe* on this CRM is transient. (Q) The ChEST-identified *if* CRM drives *LacZ* expression in the SBM (arrows). (R) In embryos expressing *lbe* ectopically in all muscle cells, expression of *LacZ* is enlarged (yellow arrow). (S) A scheme showing a model based on identity gene-dependent fine-tuning of muscle gene expression. Both direct (*if* case) and indirect (*sls* case) regulatory mechanisms are depicted. Black boxes represent exons, gray boxes represent the upstream and downstream noncoding sequences, and the light-gray boxes correspond to introns. Positions of dMef2 (Junion et al. 2005) and Lb-dependent CRMs are indicated. In pink is labeled a CRM to which binds hypothetical Lb-regulated factor X. *if* and *sls* transcription is regulated by generic dMef2-dependent modules. In the SBM context (in the presence of Lb protein) Lb binds to its intronic *if* CRM and contributes to the regulation of *if* transcription. In the case of *sls*, Lb action is indirect via an as-yet-unknown factor X. This factor most probably contributes to the activity of dMef2-dependent CRM1, which drives expression in a subset of muscles including SBM (Junion et al. 2005).

Based on presented here data we propose a model (see Fig. 2S) for direct (e.g., *if*) and indirect (e.g., *sls*) *lb*-dependent and fiber-type-specific adjustment of pan-muscular gene expression. In the direct mode Lb binds to the identified *if* CRM (Fig. 2S, red box) and together with previously described (Junion et al. 2005) generic dMef2-dependent CRMs (Fig. 2S, blue boxes) regulates fiber-type specific level of *if* expression. In an indirect mode Lb can

Based on presented here data we propose a model (see Fig. 2S) for direct (e.g., *if*) and indirect (e.g., *sls*) *lb*-dependent and fiber-type-specific adjustment of pan-muscular gene expression. In the direct mode Lb binds to the identified *if* CRM (Fig. 2S, red box) and together with previously described (Junion et al. 2005) generic dMef2-dependent CRMs (Fig. 2S, blue boxes) regulates fiber-type specific level of *if* expression. In an indirect mode Lb can

Based on presented here data we propose a model (see Fig. 2S) for direct (e.g., *if*) and indirect (e.g., *sls*) *lb*-dependent and fiber-type-specific adjustment of pan-muscular gene expression. In the direct mode Lb binds to the identified *if* CRM (Fig. 2S, red box) and together with previously described (Junion et al. 2005) generic dMef2-dependent CRMs (Fig. 2S, blue boxes) regulates fiber-type specific level of *if* expression. In an indirect mode Lb can

influence expression of another pan-muscular gene, *sls* previously found to be direct target of dMef2 (Junion et al. 2005). In this particular case Lb is expected to act indirectly via a so far unknown factor, which binds to the CRM1 (Fig. 2S, blue and pink boxes) and together with dMef2 regulates *sls* expression in lateral muscles including SBM (Fig. 2S; see Discussion for further comments; see Junion et al. 2005).

bab2 is directly regulated by *Lb* and contributes to diversification of cardiac fates

bab2 is one of the common ChEST/microarrays candidates. It has been previously reported that *bab2* is involved in leg development (Couderc et al. 2002) and in sex-specific pigmentation of the adult fly abdomen (Gompel and Carroll 2003). Thus, it was surprising to find *bab2* as an Lb target in embryos, and we first decided to analyze the embryonic expression pattern of the Bab2 protein (Fig. 3A–D). Our data clearly show that Bab2 is dynamically expressed in mesodermal cells including cardiac precursors. Triple staining with Lbe and Eve (Fig. 3A–C) show that during the early steps of cardiac development, at early stage 12, Bab2 is present in Eve-positive pericardial and dorsal muscle precursors but

is excluded from Lbe-positive cardiac cells. This specific expression underlies cardiac diversification events, which take place in stage 11 and early stage 12. Starting from the late stage 12 (Fig. 3B) weak Bab2 levels can be detected in one of the two Lb-positive cardioblasts, and slightly later (Fig. 3C) in all cardioblasts and pericardial cells. Interestingly, after cardiac tube formation Bab2 expression is maintained in all cardioblasts, and at a lower level in pericardial cells, indicating that it can also play a role in heart morphogenesis. The identification of Bab2 protein in a subset of cardiac precursors at early stage 12 (Fig. 3A) prompted us to determine whether its function was required for diversification of cardiac cells.

To address this issue we took advantage of previously described loss-of function (LOF) and GOF alleles for *bab2* (Couderc et al. 2002). As we observed that Bab2 was initially coexpressed with Eve but excluded from Lbe-positive cardiac precursors, we wondered whether Bab2 contributed to the restriction of Lbe cardiac expression by repressing its activity in neighboring Eve cells. As shown in Figure 3F (arrows), in *bab2* mutant embryos Lbe expression is enlarged and can be detected in Eve-positive cells, suggesting that Bab2 acts as a repressor of *lbe* in Eve-positive cells. The repressive potential of Bab2 during the diversification of heart cells is confirmed by

Figure 3. *bab2* expression and regulation during cardiac development. (A–D) Bab2 expression in cardiac precursors and the dorsal vessel. (A) At early stage 12 Bab2 is expressed in Eve-positive but not in Lb-positive cardiac precursors. (B) At the end of stage 12, a weak Bab2 expression starts to appear in cardioblasts including Lb-positive cells (arrows). (C) At stage 13, Bab2 is expressed in all cardiac cells. (D) After fusion of cardiac primordia, at stage 15, Bab2 protein is particularly well seen in the heart proper. (E–L) *bab2* GOF and LOF influences cell fate specification within the heart and leads to the altered positioning of cardiac precursors (shown in E,I). Wild-type stage 12 and stage 15 embryos stained for Tin, Eve, and Lbe. Note that Lbe and Eve are coexpressed with Tin but mark distinct subset of cardioblasts and pericardial cells. Arrowheads in I point to the two Lbe/Tin cardioblasts present in each hemisegment. (F,I) In *bab2* mutant embryos Lbe expression is enlarged (arrowheads in I) and appears in Eve-positive cells (arrows). (G,K) In contrast, *bab2* GOF leads to the repression of Lbe within the cardiac primordium (arrows in G; arrowheads in K). (K) Asterisks indicate lacking cardioblasts and arrows point to a supernumerary Eve-positive pericardial cell. (H,L) Triple (β3-Tubulin, Lbe, Eve) staining of stage 15 wild-type (H) and *bab2* mutant (L) embryos. Note irregular β3-Tubulin pattern (arrowheads in L) and abnormal, cardioblast-like position (arrow in L) of some Eve-positive cells in *bab2* mutants.

the overexpression of *bab2* using the *24B-GAL4* driver (Fig. 3G). In embryos with forced Bab2 expression the number of Lbe-positive cells in cardiac primordia was dramatically reduced (Fig. 3G), strongly suggesting that during early heart development Bab2 contributes to cell fate specification decisions by acting as an *lb* repressor. The cell identity function of *bab2* and its repressive influence on cardiac *lb* expression is also observed in stage 15 GOF and LOF *bab2* mutant embryos (Fig. 3 H–L). Notably, loss of *bab2* leads to the abnormal positioning of Eve-positive cells some of which coexpress Lbe and are present more dorsally at cardioblasts positions (Fig. 3L, arrow), whereas GOF of *bab2* provokes loss of some Tin-positive cardioblasts (Fig. 3K, asterisks). Alterations in cardiac cell fates and in their spatial arrangement result in affected cardiac tube morphology (Fig. 3L).

Genes downstream from lb control founder migration, myoblast fusion, and muscle attachment processes

The acquisition of cell identity is expected to involve the action of genes controlling cell movements, the establishment of contacts with neighboring cells and the development of cell type-specific functions. In *Drosophila* embryos, *lb*-expressing muscle founders undergo directed cell movements, fuse with a defined number of feeder myoblasts, and attach to the stereotypic insertion sites. *lb* is expressed during all these steps of SBM development but its role has only been reported for the initial SBM founder specification step (Jagla et al. 1998). Here we find that *lb* regulates the expression of a broad range of genes encoding extracellular matrix (ECM) components and actin-binding proteins known to control cell-cell contact and cell motility, suggesting potential role of *lb* and its targets in migration, fusion, and muscle attachment processes. To better characterize the role of *lb* in all steps of SBM formation we used muscle-targeted attenuation of *lb* function via RNAi. This allowed us to generate a range of RNAi-induced hypomorph-like SBM phenotypes (Fig. 4), which are seen in ~41% of *24B > lbRNAi* embryos (48 out of 118 embryos analyzed). Embryos presenting phenotypes can be subdivided on three categories: (1) embryos with founder migration phenotype characterized by lack of large red nucleus seen in the wild type at position indicated by the arrowhead in Figure 4C (~37%; 18 out of 48 embryos), (2) embryos with affected myoblast fusion characterized by rounded cells close to SBM indicated by arrowheads in Figure 4E (50%; 24 out of 48 embryos), and (3) embryos with affected SBM attachment characterized by the abnormal SBM shape and abnormal attachment to adjacent muscles indicated by arrowheads in Figure 4G (~13%; 6 out of 48 embryos). These data demonstrate that *lb* function is required for all these aspects of SBM development. Interestingly, muscle targeted attenuation of several *Lb* targets (Fig. 4; data not shown) leads to similar defects in SBM formation. For example, SBM founder migration was strongly affected after *24B*-targeted attenuation of *Msp300*, a microarray-identified *Lb* target known to be involved in actin cytoskeleton remodeling

(Fig. 4D). *Lb* targets appear also to contribute to myoblast fusion processes. Among them, muscle-targeted attenuation of *Mp20* encoding actin-binding protein phenocopies *lbRNAi*-induced SBM fusion phenotypes (Fig. 4, cf. E and F). The performed functional tests also suggest that *lb* targets encoding the ECM components are involved in the recognition of proper muscle attachment sites. This is particularly obvious when testing RNAi-induced attenuation of *vkg* function (Fig. 4H). However, in contrast to SBM-specific phenotypes seen in *lbRNAi* embryos, the attenuation of pan-muscular *Lb* target genes such as *Msp300* leads to the phenotypes affecting larger subsets of muscles. Thus, we propose that in the SBM context *Lb* ensures a fiber-type-specific transcriptional regulation of this class of genes (see Fig. 2S).

Functional properties of muscle and heart cells are controlled by lb

We know that *lb* expression persists in fully formed SBM muscle and can also be seen at a low level in cardiac cells after fusion of heart primordia. The functional significance of this late *lb* activity is not well understood. Here among the microarray candidates we find a large number of genes encoding muscle structure proteins (e.g., *sls*, *Prm*, *Up*, *Mhc*), ion channels (*Sh*, *CG12061*, or *CG4370*), or proteins involved in muscle contraction (*Mlc1*, *Mlc2*, *Tm*, *TpnC73F*, *bt*, *CG8698*). These findings strongly suggest that during muscle differentiation *lb* regulates the expression of genes that determine functional properties of muscle fibers raising the possibility that the composition of the sarcomeric cytoskeleton may differ from muscle to muscle. Differences in the expression of muscle structure proteins can then be associated with the identity gene-governed regulation of genes controlling muscle contraction, leading to the formation of functionally distinct muscle fibers. To test whether *lb* can control muscle contraction we analyzed expression and function of ChEST-identified direct *Lb* target, the *CG8698/Unc93* gene (Fig. 5; Supplementary Movie Fig. S3) encoding an evolutionarily conserved component of a two-pore potassium channel complex and known to be critically required for muscle contraction in *Caenorhabditis elegans* (de la Cruz et al. 2003). The *Drosophila* *CG8698* gene is specifically expressed in differentiating somatic muscles starting from stage 14, and its transcripts are particularly abundant in late embryonic stages in functional, contracting muscles (Fig. 5A–D). To determine whether *CG8698* is involved in controlling muscle contraction we used direct injection of double-stranded RNA (dsRNA) into *Mhc-tauGFP* embryos (see Materials and Methods; Estrada et al. 2006). The age-matched *Mhc-tauGFP* embryos injected with dsRNA against the *lacZ* gene (Fig. 5E; corresponding Supplementary Movies Fig. S3A,C) were compared with those injected with dsRNA against the *CG8698* gene (Fig. 5E; corresponding Supplementary Movies Fig. S3B,D). To avoid the off-target effects, two dsRNAs of ~500 nt targeting two distinct gene regions were used and effects on muscle contraction analyzed by confocal time-lapse im-

Figure 4. RNAi-based attenuation of *Lb* target genes leads to BM phenotypes similar to those observed in *lb* RNAi embryos. All panels represent lateral views of three abdominal segments from stage 15/16 embryos with focus on SBM and lateral transverse (LT) muscles. Muscles shapes are revealed with anti- β 3-Tubulin antibody. Nuclei in the SBM fiber are labeled with anti-Lbe. (A,B) Wild-type views showing shapes, insertions, and positioning of Lbe-positive nuclei in SBM muscles. Note that the SBM founder cell nuclei (the biggest Lb-expressing nuclei seen within SBM; arrows in A,B) occupy the most dorsal positions (see also schematic). Three types of SBM phenotypes observed in embryos with muscle-targeted RNAi-based attenuation of *lb* expression (C,E,G) and in embryos in which *Lb* target genes were down-regulated (D,F,H). (C,D) A similar founder migration phenotype is observed in embryos with attenuated *Lb* expression and in embryos with attenuated *Msp300* expression SBM founder (arrowheads) is no longer located dorsally (cf. A,B) leading to the altered SBM shape and to the ventral accumulation of myoblast nuclei (arrows, see also corresponding scheme). (E,F) Attenuation of *lb* function and down-regulation of *Lb* target gene *Mp20* affects

myoblast fusion. Nonfused myoblasts (arrowheads) are detected around the SBM, and no myoblast nuclei are seen in the central, narrowed part of the muscle fiber (arrow, see also scheme). (G,H) In a portion of *lb* RNAi and in *vkg* RNAi embryos SBM fibers display abnormal shapes and attachments (arrowheads, see corresponding scheme). Attachment phenotypes are often accompanied by the presence of ectopic fibers located close to SBM (arrows).

aging followed by recording of muscle size changes (Fig. 5E). In total, contractions of six SBM muscles from control injected embryos and six from embryos injected with *CG8698* dsRNA were recorded and used to obtain the mean changes in the SBM size (Fig. 5E, bottom panel). As a positive control we injected dsRNA against the *CG2708* gene previously found to block muscle contraction (Estrada et al. 2006) and observed loss of muscle contractility phenotype similar to that reported by Estrada et al. (2006) (data not shown).

This analysis clearly showed that the attenuation of *CG8698* leads to the significantly reduced muscle contractility indicating that *Lb* by regulating transcription of genes such as *CG8698*, can modulate properties of SBM contraction.

Discussion

Uncovering how the cell fate-specifying genes exert their functions and determine unique properties of cells in a tissue is central to understanding the basic rules governing normal and pathological development. To approach the cell fate determination process at a whole genome level we performed a search for transcriptional targets of the homeobox transcription factor *Lb* known to be evolutionarily conserved and required for specification of a subset of cardiac and muscular precursors. To this end

we combined the targeted expression profiling and the novel ChIP-on-chip method ChEST (Junion et al. 2005). Our data revealed an unexpectedly complex gene network operating downstream from *Lb*, which appears to act not only by regulating components of the cell identity code but also as a modulator of pan-muscular gene expression at fiber-type level. Of note, the role of *Drosophila lb* in regulating SBM founder motility appears reminiscent of the role of its vertebrate ortholog *Lbx1*, known to control the migration of leg myoblasts in mouse embryos (Vasyutina et al. 2005).

The *Lb*-regulated components of the cell identity code

Earlier genetic studies revealed that within the same competence domain the cell fate specifying factors acted as repressors to down-regulate genes determining the identity of neighboring cells (Jagla et al. 2002). Consistent with this finding, *Lb* was found to repress *msh* and *kruppel* (*kr*) during diversification of lateral muscle precursors (Jagla et al. 1998, 1999) and *even skipped* (*eve*) within the heart primordium (Jagla et al. 1997, 2002). Here we find that additional identity code components are regulated negatively by *Lb*. In the lateral muscle domain *Lb* acts as a repressor of the *MyoD* ortholog *nau* and the NK homeobox gene *slou* (Fig. 2C–F), both known to be required for the specification of a subset of somatic

Figure 5. *CG8698*, a ChEST-identified Lb target gene is specifically expressed in differentiating muscle fibers and required for muscle contraction. Lateral views of stage 14 (A,B) and stage 16 (C,D) embryos stained for *CG8698* RNA (red), *Lbe* (green), and *dMef2* protein (blue). (B,D) *CG8698* is expressed specifically in differentiating somatic muscle fibers (coexpression with *dMef2*). Notice that *CG8698* is also expressed in Lb-positive SBM (arrows in A). (E, top panel) A chart representing changes in the SBM size recorded in *Mhc-tauGFP* embryos injected with dsRNA against the *lacZ* gene (green plot) or against the *CG8698* gene (red plot). Notice the significantly reduced fluctuations in the SBM size in embryos with RNAi-attenuated expression of *CG8698*. (Bottom panel) A chart representing mean changes in the SBM size recorded from six SBM muscles in the control condition (*lacZ*-RNAi) and after attenuation of *CG8698* (*CG8698*-RNAi) (see Materials and Methods for details). Muscle size changes were recorded from time-lapse movies (see Supplementary Movie Fig. S3) and analyzed using Volocity Measurement software (Improvision). Deviations from the mean size changes are represented by the error bars.

muscles (Paterson et al. 1991; Knirr et al. 1999). This suggests that a particularly complex network of transcription factors [Ap, Msh, Kr, Nau, Slou] controls the specification of individual muscle fates in the lateral domain. Interestingly, none of these factors is coexpressed with *lb* in the SBM, which appears to be a functionally distinct muscle requiring a specific developmental program. Besides factors with well-documented roles in di-

versification of muscle fibers, our global approach identified a few novel potential players in the muscle identity network. Among them are expressed in somatic muscle precursors the *Pdp1* gene encoding Par domain factor (Reddy et al. 2000) and the *CG32611* gene containing a zinc finger motif (see Table 1).

Interestingly, in the cardiac domain our data demonstrate that *lb* is able to positively regulate the expression of *tin* and the effector of RTK pathway *pointed* (*pnt*), both involved in cardiac cell fate specification (Alvares et al. 2003; Zaffran et al. 2006). These findings are consistent with earlier observations that the forced *lb* expression leads to the ectopic *tin*-positive cells within the dorsal vessel (Jagla et al. 2002). Also, during early cardiogenesis *lb* directly represses *bric a brac 2* (*bab2*), which emerges as a novel component of the genetic cascade controlling the diversification of cardiac cells. Thus, the ability of Lb to act either as repressor or as activator suggests a context-dependent interaction with cofactors. Of note, several microarray identified Lb targets have also been found in the RNAi-based screen for genes involved in heart morphogenesis (see Supplementary Table S5; Kim et al. 2004).

Identity gene-dependent modulation of muscle gene expression

Our data indicate that *lb* exerts its muscle identity functions via regulation of pan-muscular genes that control cell movements, cell shapes and cell-cell interactions including myoblast fusion, myotube growth, and attachment events.

Regulation of *if* (see Fig. 2S) provides an example of how the cell-type-specific fine-tuning of expression can be achieved for genes expressed in all muscle precursors. We reported previously (Junion et al. 2005) that *if* is directly regulated by *dMef2* via two intronic CRMs (Fig. 2S), which most probably ensure a generic muscle-specific *if* expression. Here, we identify a distinct, Lb-dependent *if* CRM able to drive expression in a restricted subset of muscles including the SBM, thus indicating that the *if* transcription is regulated by a coordinated action of generic and muscle-type-specific CRMs (Fig. 2S). Identification of Lb-dependent CRM close to *if* also indicates that *lb* may contribute to the *dMef2*-regulated feed-forward loops (Sandmann et al. 2006). Such a modular regulation of transcription levels would provide an efficient way for precise, fiber-type-specific setting of muscle genes activity. As shown for *if* in the SBM context, this regulation is expected to be direct via the identified here Lb-binding module (Fig. 2S). Our data also suggest that a similar muscle-type-specific transcriptional regulation can be achieved in an indirect mode. For example, the pan-muscular *kettin/sls* gene encoding a giant protein required for the formation and maintenance of normal sarcomere structure is regulated by three distinct *dMef2*-binding CRMs (Fig. 2S) able to drive expression in a muscle-type-specific manner (Junion et al. 2005). Among them, CRM 1 located upstream the gene was found to drive expression in a subset of ventral and lateral

muscles including SBM (Junion et al. 2005). Here we identify *sIs* as an Lb target in the microarray screen, and demonstrate that in embryos overexpressing Lb the *sIs* expression is up-regulated (Fig. 2H). These findings suggest that Lb can act via an as-yet-unknown factor to modulate *sIs* expression in the SBM (Fig. 2S).

A model for Lb-governed multistep acquisition of muscular and cardiac fates

The reported here Lb targets fit into three main categories: (1) genes encoding transcription factors contributing to cell-type-specific identity gene code; (2) genes controlling cell shapes, adhesion, and cell motility; and (3) late-acting genes required for functional properties of cardiac and muscle cells (Fig. 6A). Importantly, Lb is able to bind to enhancers of genes from all these categories (Fig. 6B, red-labeled genes). Also, the functional properties of identified Lb targets strongly suggest that Lb-dependent multistep acquisition of cell identity is executed in a similar way in cardiac and in muscle cells (Fig. 6B). With respect to the Lb targets encoding transcription factors we identify *bab2* as a new component of cardiac cell identity code. Considering the regulation of cell shape, cell adhesion, and motility, a large number of Lb targets code for proteins involved in remodeling of the actin cytoskeleton, for the ECM components and for integrins. Down-regulation of the selected microarray candidates from this category (Fig. 6B, pink-labeled genes) leads to dramatic muscle phenotypes affecting founder migration, myoblast fusion or muscle fiber attachment. Among the late-acting genes, we analyzed expression and function of a direct, ChEST-identified Lb target gene, *CG8698*, and demonstrated that it is specifically expressed in differentiated muscles and required for muscle contraction.

Thus, we conclude that the Lb-governed acquisition of cell identity is a long-term process (1) initiated by the spatially restricted expression of a set of transcription factors and (2) executed by precise regulation of genes determining the morphological, dynamic and functional properties specific to a given muscle or heart cell type.

Materials and methods

Targeted expression profiling of lb GOF and LOF embryos

As presented in Figure 1, two different drivers [*24B-GAL4* and *tin-GAL4*] were used for crosses with *UAS-lbe* and *UAS-lbRNAi* lines to obtain heart (H) and muscle plus heart (M + H)-specific targeting conditions. The *24B-Gal4* (*P[GawB]/how^{24B}*) was provided by Bloomington Stock Center (BL 1767) and *tin-GAL4* (gift from R. Bodmer, Burnham Institute, San Diego, CA) was described in Zikova et al. (2003). Aged (5- 16-h-AEL-old) embryos were collected. One-hundred embryos were homogenized, and RNA was isolated using Trizol Reagent (Gibco) and purified using MessageClean (GenHunter) following the manufacturer's protocols. Three independent RNA isolations were performed for each of five genetic contexts and used to produce probes for microarrays. The Affymetrix cDNA *Drosophila* Genome Arrays were used.

Multistep acquisition of cell identity

Figure 6. A genome-wide revised view of Lb-governed cell fate specification. (A) A scheme showing that Lb acts at three different levels. Initially, it contributes to setting the so-called identity code by regulating negatively or positively other muscle- and heart-specific transcription factors. In the next step, Lb regulates genes required for the acquisition of cell-type-specific properties such as motility, shape, size, position, and cell-cell interactions. Lastly, Lb appears involved in regulation of genes required for terminal differentiation and the functional properties of muscle and cardiac cells. (B) A scheme showing that Lb targets are involved in all major steps of muscle and cardiac cell development. Note that the action of Lb at multiple levels and over a long time period is consistent with its expression during all steps of myogenesis and cardiogenesis. The direct Lb target genes identified by ChEST are labeled in red, and the pink-labeled genes correspond to microarray targets tested functionally by RNAi-based down-regulation.

Analysis of microarray data

Primary data analysis was performed using the GeneChip Microarray Suite (MAS) 5.0 algorithms (Affymetrix) with default parameters and global scaling as a normalization method (target intensity = 100). Reproducibility was ensured by using probes corresponding to three independent RNA extractions for each genetic context.

The Significance Analysis of Microarray Data (SAM) implemented in the TIGR MeV version 3.1 software (http://www.tm4.org/scgi-bin/getprogram.cgi?program=mev_old) was used to identify those genes that had statistically significant differences in expression between Ladybird GOF and LOF embryos and wild-type embryos. Parameters were set as specified below to analyze two-class, unpaired data: 1000 permutations, k-nearest neighbor imputer with 10 neighbours and newly initialized random number seeds for each analysis. FDR was varied

between 0.05 and 0.1 for evaluation of changes in the number of significant genes.

In *lb* GOF conditions, genes with a *q* value <5.75 and a fold change of more than +1.5 or less than -1.5 with respect to the wild type were considered to be regulated by *lb*. In the context of RNAi-based *lb* attenuation, we applied a higher *q* value of <10 (H + M conditions) and <7.5 (H conditions). This was due to the incomplete RNAi-mediated attenuation of *lb* (Maqbool et al. 2006). The fold change cutoff values (+1.5, -1.5) were as for GOF experiments. The candidate genes were classified according to their GO annotations using DAVID software (<http://david.abcc.ncifcrf.gov>) and according to the embryonic expression profile. To validate microarray data the expression of some of the candidates were tested by RT-PCR, real-time RT-PCR, or by antibody staining.

Validation of microarray candidates by RT-PCR and by real-time RT-PCR

Mutant and wild-type embryos from stages 11–15 were collected. Total RNA was extracted with the Trizol Reagent (Gibco), and reverse transcription was performed on 0.5 µg of total RNA with the SuperScript III kit (Invitrogen). RT-PCR conditions were 30 sec, 94°C; hybridization temperature: according to T_m, 60 sec; 72°C, 60 sec, repeated 40 times. RT-PCR product aliquots were taken for semiquantitative analysis at cycles 30, 35, and 40. Real-time RT-PCR was performed on 2 µL of cDNA using the LC-FastStart DNA Master SGI PCR amplification kit (Roche Diagnostics) and the LightCycler Carousel-Based system (Roche Diagnostics). The real-time PCR conditions were as follows: denaturation 10 min, 95°C; 45 cycles; denaturation 10 sec, 95°C; hybridization: T_m primer 5 sec, 5°C, elongation 30 sec, 72°C. Fusion curve: denaturation 95°C, 0 sec, hybridization 65°C, 15 sec, melting 95°C, 0 sec. As an internal control the *ribosomal protein 49* gene, *rp49*, was amplified. List of RT-PCR and real-time RT-PCR primers used to test candidate gene expression is provided in the Supplemental Material. The quantification of RT-PCR and real-time RT-PCR validation tests is provided in Supplementary Table S8. To compare relative gene expression between the wild-type and the Lb-GOF or Lb-LOF conditions in real-time RT-PCR reactions, we used the $\Delta\Delta C_t$ method (Livak and Schmittgen 2001), where the relative quantity to the calibrator was determined as $2^{-(\Delta\Delta C_t)}$.

ChEST approach

The ChEST approach was used as described previously (Junion et al. 2005). Various combinations of binding sites of Lb, Twist (basic helix-loop-helix [bHLH]), Yan (ETS), dMef2, dTCF, and Tin were used to identify potential Lb-dependent CRMs (Supplemental Material). The Lb consensus binding site was determined using the SELEX approach and then tested by gel shift assay (see below; Supplemental Material). The set of binding sites including Tin and dMef2 was defined to select heart- and muscle-specific Lb target genes. The applied genome scanning conditions and the subsequent filtering procedure using SCAFI software (Junion et al. 2005) are presented in the Supplemental Material. For each of the in silico-identified regulatory sequences, a pair of primers was defined and the sequence was amplified by PCR, purified, and spotted on a nylon membrane to obtain a computed LB CRM array. The DNA immunoprecipitated with anti-Lb antibody and the control DNA (ChIP with nonimmune serum) were used as templates for the synthesis of the probes, which were then hybridized to the generated CRM array.

Purification of His fusion proteins and identification of Lb consensus binding site by SELEX

Both the *lbe* and *lbi* homeodomain encoding DNA fragments as well as full protein-coding sequences have been cloned in His-Tag-pET expression vector (pET-45b+, Novagen). DNA fragments were amplified by PCR using primers carrying appropriate restriction sites and then directionally cloned into the linearized His-Tag-pET vector. Protein purification was performed according to the manufacturer's protocols. Isolated His fusion proteins were affinity-purified on agarose NTA beads (Novagen) and used for the oligonucleotide selection procedure (SELEX) as described in the Supplemental Material and according to Chittenden et al. (1991). For the gel retardation assay, double-stranded oligonucleotides containing the Lb-binding sites were PAGE-purified prior to radioactive labeling. Five picomoles of oligonucleotides were 5'-phosphorylated with T4 polynucleotide kinase (New England Biolabs) using 2.5 µL of [α -³²P]-ATP (6000 Ci/mmol; Amersham) in a total volume of 20 µL. Probes were PAGE-purified, extracted, and precipitated with ethanol. Pellets were dissolved in 5 mM Tris-HCl (pH 8.0), 50 mM NaCl, and 0.5 mM EDTA. His-Tag fusion proteins were diluted in PBS containing 200 µg/mL BSA, 1 mM EDTA, and 1 mM DTT. Unless indicated otherwise, 100 ng of protein were incubated with the labeled probe (25,000 counts per minute [cpm]) in binding buffer [20 mM HEPES at pH 7.0, 50 mM KCl, 4 mM MgCl₂, 4% Ficoll, 5% glycerol, 0.2 mM EDTA, 0.5 mM DTT, 500 ng poly-(dI-dC)] for 20 min at room temperature. Five-microliter aliquots were loaded on 5% polyacrylamide gels and electrophoresed at 4°C in 0.5× TBE. Gels were dried and visualized by autoradiography.

Generation of transgenic lines and validation of ChEST-identified targets

ChEST-identified Lb-dependent CRMs were cloned upstream of *lacZ* or *GFP* reporter genes and then used for germline transformations to generate transgenic *Drosophila* lines. Reporter gene expression was revealed in whole-mount embryos double-stained with rabbit anti-LacZ, 1:1000 (Sigma), goat anti-GFP (1:300) (Biogenesis), and mouse anti-Lbe, 1:5000. To check whether the CRM-driven expression of reporter gene was Lb dependent, its expression was tested in an *lb* GOF context. To determine the embryonic expression of *bab2* we used rat anti-Bab2 antibodies (1:2000) (kindly provided by J.-L. Couderc). We also used guinea pig anti-Eve (1:200) and rabbit anti-Slou (1:500) (gift of M. Frasch), rabbit anti-Nau (1:50) (from B. Patterson), guinea pig anti-Msp300 (1:1000) (provided by T. Volk), rat anti-If (1:2) (gift of N. Brown), rabbit anti-Tin (1:800) (from M. Frasch), rabbit anti-dMef2 (1:2000) (from H. Nguyen), and rabbit anti- β 3-Tubulin (1:5000) (from R. Renkawitz-Pohl). The *bab2* mutant alleles *bab2^{E5}* and *bab2^{E1}* and the *uas-bab2* line (Couderc et al. 2002) were used to analyze the role of *bab2* in cardiac development.

Testing functions of Lb microarray targets by muscle-targeted RNAi

The following *uas*-RNAi lines from the NIG-Fly collection (<http://www.shigen.nig.ac.jp/fly/nigfly>) were used to test functions of Lb target genes from microarrays screen: *UAS-Msp300RNAi* Ref. 31916R-1, *UAS-Mp20RNAi* Ref. 4696R-4, and *UAS-vkgRNAi* Ref. 16858R-1. The *uas*-RNAi lines for candidate genes as well as the *UAS-lbRNAi* line, targeting both *lbe* and *lbi* (Maqbool et al. 2006), were crossed with a *24B-GAL4* driver, and the F1 embryos were double-stained for β 3-Tubulin and Lbe and analyzed for muscle phenotypes.

Analysis of CG8698 expression pattern and its role in muscle contraction

CG8698 cDNA (GH09628, DGRC gold collection) clone was used to prepare a Dig-labeled antisense RNA probe according to standard procedure (Tautz and Pfeifle 1989). Fluorescent in situ hybridization with TSA amplification system (Perkin-Elmer) was done as described previously (Junion et al. 2005) and followed by anti-dMef2 (1:2000) and anti-Lbe (1:5000) stainings to reveal embryonic muscle cells. Triple-labeled embryos were analyzed using an LSM510 Meta (Zeiss) confocal microscope. To test the role of CG8698 in muscle contraction, we used a previously described approach (Estrada et al. 2006) based on direct dsRNA injection into *Mhc-tauGFP* embryos. To avoid off-target effects for each gene tested, two distinct gene segments of 400–600 base pairs (bp) in length were selected for dsRNA synthesis. These sequences were PCR-amplified from genomic DNA using primers flanked by T7 promoters on both ends (see primer sequences listed below). PCR products were purified and transcribed in vitro using the RiboMax T7 In vitro transcription system (Promega). dsRNA was diluted to the concentration of 2 mg/mL in water for embryo transfer (Sigma) and injected mid-ventrally into dechorionated, syncytial blastoderm-staged *Mhc-tauGFP* embryos. About 50 injected embryos were analyzed for each dsRNA probe. Injection of *lacZ* dsRNA was used as a negative control and the CG2708 dsRNA (Estrada et al. 2006) was used as a positive control. Muscle contraction was monitored using an Olympus FV300 confocal microscope (frame capture every 5 sec) and processed to make movies by Volocity software (Improvision). In total, the muscle contractions of 10 *lacZ*-RNAi embryos and 10 CG8698-RNAi embryos were recorded. To define the mean changes in the SBM size due to the muscle contractions, three embryos for each context were selected (by criteria of their orientation to visualize SBMs) and two distinct SBM muscles per selected embryo were analyzed. A Volocity Measurement module was used to analyze time-lapse movies and to plot size changes of individual muscle fibers during contraction.

The microarray data sets are available via <http://www.ebi.ac.uk/arrayexpress>. ArrayExpress accession number E-TABM-297.

Acknowledgments

We are grateful to C. Girardot for help in microarray data submission, S. Bassot for help in setting real-time RT-PCR conditions, and Soluscience SA for designing bioinformatics tools for CRM scanning and data set comparisons. This work was supported by the Institut National de la Santé et de la Recherche Médicale, the Association Française contre les Myopathies, the Association pour la Recherche sur le Cancer, and European Grant LSHG-CT-2004-511978 to the MYORES Network of Excellence.

References

- Alvares, L.E., Schubert, F.R., Thorpe, C., Mootoosamy, R.C., Cheng, L., Parkyn, G., Lumsden, A., and Dietrich, S. 2003. Intrinsic, Hox-dependent cues determine the fate of skeletal muscle precursors. *Dev. Cell* **3**: 379–390.
- Baylies, M.K. and Michelson, A.M. 2001. Invertebrate myogenesis: Looking back to the future of muscle development. *Curr. Opin. Genet. Dev.* **11**: 431–439.
- Bloor, J.W. and Brown, N.H. 1998. Genetic analysis of the *Drosophila* α PS2 integrin subunit reveals discrete adhesive, morphogenetic and sarcomeric functions. *Genetics* **148**: 1127–1142.
- Briscoe, J., Pierani, A., Jessell, T.M., and Ericson, J. 2000. A homeodomain protein code specifies progenitor cell identity and neuronal fate in the ventral neural tube. *Cell* **101**: 435–445.
- Brohmann, H., Jagla, K., and Birchmeier, C. 2000. The role of Lbx1 in migration of muscle precursor cells. *Development* **127**: 437–445.
- Brown, N.H., Gregory, S.L., and Martin-Bermudo, M.D. 2000. Integrins as mediators of morphogenesis in *Drosophila*. *Dev. Biol.* **223**: 1–16.
- Buckingham, M. 2003. How the community effect orchestrates muscle differentiation. *Bioessays* **25**: 13–16.
- Carmena, A., Gisselbrecht, S., Harrison, J., Jimenez, F., and Michelson, A.M. 1998. Combinatorial signaling codes for the progressive determination of cell fates in the *Drosophila* embryonic mesoderm. *Genes & Dev.* **12**: 3910–3922.
- Certel, S.J. and Thor, S. 2004. Specification of *Drosophila* motoneuron identity by the combinatorial action of POU and LIM-HD factors. *Development* **131**: 5429–5439.
- Cheng, L., Samad, O.A., Xu, Y., Mizuguchi, R., Luo, P., Shirasawa, S., Goulding, M., and Ma, Q. 2005. Lbx1 and Tlx3 are opposing switches in determining GABAergic versus glutamatergic transmitter phenotypes. *Nat. Neurosci.* **11**: 1510–1515.
- Chittenden, T., Livingston, D.M., and Kaelin Jr., W.G. 1991. The T/E1A-binding domain of the retinoblastoma product can interact selectively with a sequence-specific DNA-binding protein. *Cell* **65**: 1073–1082.
- Couderc, J.L., Godt, D., Zollman, S., Chen, J., Li, M., Tjong, S., Cramton, S.E., Sahut-Barnola, I., and Laski, F.A. 2002. The bric a brac locus consists of two paralogous genes encoding BTB/POZ domain proteins and acts as a homeotic and morphogenetic regulator of imaginal development in *Drosophila*. *Development* **129**: 2419–2433.
- De Graeve, F., Jagla, T., Daponte, J.P., Rickert, C., Dastugue, B., Urban, J., and Jagla, K. 2004. The ladybird homeobox genes are essential for the specification of a subpopulation of neural cells. *Dev. Biol.* **270**: 122–134.
- de la Cruz, I.P., Levin, J.Z., Cummins, C., Anderson, P., and Horvitz, H.R. 2003. sup-9, sup-10, and unc-93 may encode components of a two-pore K⁺ channel that coordinates muscle contraction in *Caenorhabditis elegans*. *J. Neurosci.* **23**: 9133–9145.
- Estrada, B., Choe, S.E., Gisselbrecht, S.S., Michaud, S., Raj, L., Busser, B.W., Halfon, M.S., Church, G., and Michelson, A.M. 2006. An integrated strategy for analyzing the unique developmental programs of different myoblast subtypes. *PLoS Genet.* **2**: e16. doi: 10.1371/journal.pgen.0020016.
- Fichelson, P., Audibert, A., Simon, F., and Gho, M. 2005. Cell cycle and cell-fate determination in *Drosophila* neural cell lineages. *Trends Genet.* **21**: 413–420.
- Frasch, M. 1999a. Intersecting signalling and transcriptional pathways in *Drosophila* heart specification. *Semin. Cell Dev. Biol.* **10**: 61–71.
- Frasch, M. 1999b. Controls in patterning and diversification of somatic muscles during *Drosophila* embryogenesis. *Curr. Opin. Genet. Dev.* **9**: 522–529.
- Gompel, N. and Carroll, S.B. 2003. Genetic mechanisms and constraints governing the evolution of correlated traits in drosophilid flies. *Nature* **424**: 931–935.
- Gross, M.K., Moran-Rivard, L., Velasquez, T., Nakatsu, M.N., Jagla, K., and Goulding, M. 2000. Lbx1 is required for muscle precursor migration along a lateral pathway into the limb. *Development* **127**: 413–424.

- Halfon, M.S., Carmona, A., Gisselbrecht, S., Sackerson, C.M., Jimenez, F., Baylies, M.K., and Michelson, A.M. 2000. Ras pathway specificity is determined by the integration of multiple signal-activated and tissue-restricted transcription factors. *Cell* **103**: 63–74.
- Jagla, K., Frasch, M., Jagla, T., Dretzen, G., Bellard, F., and Bellard, M. 1997. ladybird, a new component of the cardiogenic pathway in *Drosophila* required for diversification of heart precursors. *Development* **124**: 3471–3479.
- Jagla, T., Bellard, F., Lutz, Y., Dretzen, G., Bellard, M., and Jagla, K. 1998. ladybird determines cell fate decisions during diversification of *Drosophila* somatic muscles. *Development* **125**: 3699–3708.
- Jagla, T., Bellard, F., Vonesch, J.L., Bellard, M., Dastugue, B., and Jagla, K. 1999. Plasticity within the lateral somatic mesoderm of *Drosophila* embryos. *Int. J. Dev. Biol.* **43**: 571–573.
- Jagla, T., Bidet, Y., Da Ponte, J.P., Dastugue, B., and Jagla, K. 2002. Cross-repressive interactions of identity genes are essential for proper specification of cardiac and muscular fates in *Drosophila*. *Development* **129**: 1037–1047.
- Junion, G., Jagla, T., Duplant, S., Tapin, R., Da Ponte, J.P., and Jagla, K. 2005. Mapping Dmef2-binding regulatory modules by using a ChIP-enriched in silico targets approach. *Proc. Natl. Acad. Sci.* **102**: 18479–18484.
- Kim, Y.O., Park, S.J., Balaban, R.S., Nirenberg, M., and Kim, Y. 2004. A functional genomic screen for cardiogenic genes using RNA interference in developing *Drosophila* embryos. *Proc. Natl. Acad. Sci.* **101**: 159–164.
- Knirr, S., Azpiazu, N., and Frasch, M. 1999. The role of the NK-homeobox gene slouch (S59) in somatic muscle patterning. *Development* **126**: 4525–4535.
- Lee, H.H. and Frasch, M. 2000. Wingless effects mesoderm patterning and ectoderm segmentation events via induction of its downstream target sloppy paired. *Development* **127**: 5497–5508.
- Liu, J., Qian, L., Wessells, R.J., Bidet, Y., Jagla, K., and Bodmer, R. 2006. Hedgehog and RAS pathways cooperate in the anterior-posterior specification and positioning of cardiac progenitor cells. *Dev. Biol.* **290**: 373–385.
- Livak, K.J. and Schmittgen, T.D. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the $2(-\Delta\Delta C(T))$ method. *Methods* **25**: 402–408.
- Maqbool, T., Soler, C., Jagla, T., Daczewska, M., Lodha, N., Palliyil, S., Vijayraghavan, K., and Jagla, K. 2006. Shaping leg muscles in *Drosophila*: Role of ladybird, a conserved regulator of appendicular myogenesis. *PLoS ONE* **1**: e122. doi: 10.1371/journal.pone.0000122.
- Mootosamy, R.C. and Dietrich, S. 2002. Distinct regulatory cascades for head and trunk myogenesis. *Development* **129**: 573–583.
- Neyt, C., Jagla, K., Thisse, C., Thisse, B., Haines, L., and Currie, P.D. 2000. Evolutionary origins of vertebrate appendicular muscle. *Nature* **408**: 82–86.
- Olson, E.N. 2006. Gene regulatory networks in the evolution and development of the heart. *Science* **313**: 1922–1927.
- Paterson, B.M., Walldorf, U., Eldridge, J., Dubendorfer, A., Frasch, M., and Gehring, W.J. 1991. The *Drosophila* homologue of vertebrate myogenic-determination genes encodes a transiently expressed nuclear protein marking primary myogenic cells. *Proc. Natl. Acad. Sci.* **88**: 3782–3786.
- Philippakis, A.A., Busser, B.W., Gisselbrecht, S.S., He, F.S., Estrada, B., Michelson, A.M., and Bulyk, M.L. 2006. Expression-guided in silico evaluation of candidate cis regulatory codes for *Drosophila* muscle founder cells. *PLoS Comput. Biol.* **2**: e53. doi: 10.1371/journal.pcbi.0020053.
- Rebeiz, M., Reeves, N.L., and Posakony, J.W. 2002. SCORE: A computational approach to the identification of cis-regulatory modules and target genes in whole-genome sequence data. Site clustering over random expectation. *Proc. Natl. Acad. Sci.* **99**: 9888–9893.
- Reddy, K.L., Wohlwill, A., Dzitoeva, S., Lin, M.H., Holbrook, S., and Storti, R.V. 2000. The *Drosophila* PAR domain protein 1 (Pdp1) gene encodes multiple differentially expressed mRNAs and proteins through the use of multiple enhancers and promoters. *Dev. Biol.* **224**: 401–414.
- Riechmann, V. and Ephrussi, A. 2001. Axis formation during *Drosophila* oogenesis. *Curr. Opin. Genet. Dev.* **11**: 374–383.
- Roulet, E., Busso, S., Camargo, A.A., Simpson, A.J., Mermod, N., and Bucher, P. 2002. High-throughput SELEX SAGE method for quantitative modeling of transcription-factor binding sites. *Nat. Biotechnol.* **20**: 831–835.
- Sandmann, T., Jensen, L.J., Jakobsen, J.S., Karzynski, M.M., Eichenlaub, M.P., Bork, P., and Furlong, E.E. 2006. A temporal map of transcription factor activity: mef2 directly regulates target genes at all stages of muscle development. *Dev. Cell* **10**: 797–807.
- Skeath, J.B. 1999. At the nexus between pattern formation and cell-type specification: The generation of individual neuroblast fates in the *Drosophila* embryonic central nervous system. *Bioessays* **21**: 922–931.
- Tautz, D., and Pfeifle, C. 1989. A non-radioactive in situ hybridization method for the localization of specific RNAs in *Drosophila* embryos reveals translational control of the segmentation gene hunchback. *Chromosoma* **98**: 81–85.
- Vasyutina, E., Stebler, J., Brand-Saberi, B., Schulz, S., Raz, E., and Birchmeier, C. 2005. CXCR4 and Gab1 cooperate to control the development of migrating muscle progenitor cells. *Genes & Dev.* **19**: 2187–2198.
- Xu, X., Yin, Z., Hudson, J.B., Ferguson, E.L., and Frasch, M. 1998. Smad proteins act in combination with synergistic and antagonistic regulators to target Dpp responses to the *Drosophila* mesoderm. *Genes & Dev.* **12**: 2354–2370.
- Zaffran, S. and Frasch, M. 2002. Early signals in cardiac development. *Circ. Res.* **91**: 457–469.
- Zaffran, S., Reim, I., Qian, L., Lo, P.C., Bodmer, R., and Frasch, M. 2006. Cardioblast-intrinsic Tinman activity controls proper diversification and differentiation of myocardial cells in *Drosophila*. *Development* **133**: 4073–4083.
- Zhou, Q. and Wong, W.H. 2004. CisModule: De novo discovery of cis-regulatory modules by hierarchical mixture modeling. *Proc. Natl. Acad. Sci.* **101**: 12114–12119.
- Zikova, M., Dastugue, B., and Jagla, K. 2003. Patterning of the cardiac outflow region in *Drosophila*. *Proc. Natl. Acad. Sci.* **100**: 12189–12194.

Genome-wide view of cell fate specification: *ladybird* acts at multiple levels during diversification of muscle and heart precursors

Guillaume Junion, Laetitia Bataillé, Teresa Jagla, et al.

Genes Dev. 2007, **21**:

Access the most recent version at doi:[10.1101/gad.437307](https://doi.org/10.1101/gad.437307)

Supplemental Material

<http://genesdev.cshlp.org/content/suppl/2007/11/15/21.23.3163.DC1>

References

This article cites 50 articles, 21 of which can be accessed free at:
<http://genesdev.cshlp.org/content/21/23/3163.full.html#ref-list-1>

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

Focused on your science.

USC
SCIENTIFIC
SIDE BY SCIENCE